RGEN - REPLIGEN CORP
Region: US
Website: repligen.com
Employees: 2,020
IPO year: 1990
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company sells its products to life sciences, biopharmaceutical companies; laboratory researchers; and contract manufacturing organizations.
Repligen (RGEN) Q1 Earnings: What To Expect
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what to look for.
Read more3 Healthcare Stocks That Concern Us
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 10.9%. This drawdown was worse than the S&P 500’s 5.7% decline.
Read moreWill Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?
Repligen (RGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read more